References
- Hochman MA, Seery CM, Zarbin MA. Pathophysiology and management of subretinal hemorrhage. Surv Ophthalmol. [Internet]. 1997 [cited 2019 Feb 19];42:195–213. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9406367
- Group SST (SST) R. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology. [Internet]. 2004 [cited 2019 Feb 20];111:1993–2006. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15522364
- Avery RL, Fekrat S, Hawkins BS, et al. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina. [Internet]. 1996 [cited 2019 Feb 20];16:183–189. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8789855
- Chang YS, Kim JH, Kim JW, et al. Development of submacular hemorrhage in neovascular age-related macular degeneration: influence on visual prognosis in a clinical setting. Korean J Ophthalmol. [Internet]. 2018 [cited 2019 Feb 26];32:361. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30311458
- Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res. [Internet]. 2007 [cited 2019 Feb 20];13:2825–2830. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17504979
- Adamis AP, Shima DT, Yeo KT, et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun. [Internet]. 1993 [cited 2019 Feb 20];193:631–638. Available from: https://www.sciencedirect.com/science/article/pii/S0006291X83716712
- Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res. [Internet]. 2010 [cited 2019 Feb 20];87:262–271. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20400620
- Stefánsson E, Geirsdóttir Á, Sigurdsson H. Metabolic physiology in age related macular degeneration. Prog Retin Eye Res. [Internet]. 2011 [cited 2019 Mar 27];30:72–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20951826
- Coleman DJ, Silverman RH, Rondeau MJ, et al. Age-related macular degeneration: choroidal ischaemia? Br J Ophthalmol. [Internet]. 2013 [cited 2019 Mar 27];97:1020–1023. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23740965
- Ying G, Maguire MG, Daniel E, et al. Association between antiplatelet or anticoagulant drugs and retinal or subretinal hemorrhage in the comparison of age-related macular degeneration treatments trials. Ophthalmology. [Internet]. 2016 [cited 2019 Feb 21];123:352–360. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26545320
- Sun MT, Wood MK, Chan W, et al. Risk of intraocular bleeding with novel oral anticoagulants compared with warfarin: a systematic review and meta-analysis. JAMA Ophthalmol. [Internet]. 2017 [cited 2019 Feb 21];135:864–870. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28687831
- Talany G, Guo M, Etminan M. Risk of intraocular hemorrhage with new oral anticoagulants. Eye. [Internet]. 2017 [cited 2019 Feb 21];31:628–631. Available from: http://www.nature.com/articles/eye2016265
- Fine HF, Iranmanesh R, Del Priore LV, et al. Surgical outcomes after massive subretinal hemorrhage secondary to age-related macular degeneration. Retina. [Internet]. 2010 [cited 2019 Feb 26];30:1588–1594. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20856172
- Toth CA, Morse LS, Hjelmeland LM, et al. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol (Chicago, Ill 1960). [Internet]. 1991 [cited 2019 Feb 21];109:723–729. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2025175
- Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. [Internet]. 1982 [cited 2019 Feb 20];94:762–773. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7180915
- Sanders D, Peyman GA, Fishman G, et al. The toxicity of intravitreal whole blood and hemoglobin. Albrecht Von Graefes Arch Klin Exp Ophthalmol. [Internet]. 1975 [cited 2019 Feb 21];197:255–267. Available from: http://www.ncbi.nlm.nih.gov/pubmed/813541
- Ueda K, HJ K, Zhao J, et al. Iron promotes oxidative cell death caused by bisretinoids of retina. Proc Natl Acad Sci. [Internet]. 2018 [cited 2019 Feb 21];115:4963–4968. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29686088
- Wade EC, Flynn HW, Olsen KR, et al. Subretinal hemorrhage management by pars plana vitrectomy and internal drainage. Arch Ophthalmol (Chicago, Ill 1960). [Internet]. 1990 [cited 2019 Feb 21];108:973–978. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2369357
- Ibanez HE, Williams DF, Thomas MA, et al. Surgical management of submacular hemorrhage. A series of 47 consecutive cases. Arch Ophthalmol (Chicago, Ill 1960). [Internet]. 1995 [cited 2019 Feb 21];113:62–69. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7826295
- Zhao P, Hayashi H, Oshima K, et al. Vitrectomy for macular hemorrhage associated with retinal arterial macroaneurysm. Ophthalmology. [Internet]. 2000 [cited 2019 Feb 21];107:613–617. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10711904
- Rubsamen PE, Flynn HW, Civantos JM, et al. Treatment of massive subretinal hemorrhage from complications of scleral buckling procedures. Am J Ophthalmol. [Internet]. 1994 [cited 2019 Feb 21];118:299–303. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8085585
- Submacular Surgery Trials (SST) Manual of Procedures. NTIS report no. 199822 [Internet]. Natl Tech Reports Libr - NTIS. 1998 [cited 2019 Apr 1]. Available from: https://ntrl.ntis.gov/NTRL/dashboard/searchResults/titleDetail/PB98166648.xhtml
- Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology. [ Internet]. 2004 [cited 2019 Mar 27];111:1967–1980. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15522362
- Giansanti F, Eandi CM, Virgili G. Submacular surgery for choroidal neovascularisation secondary to age-related macular degeneration. Cochrane Database Syst Rev. [Internet]. 2009 [cited 2019 Feb 21];CD006931. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19370663
- Binder S, Krebs I, Hilgers R-D, et al. Outcome of Transplantation of Autologous Retinal Pigment Epithelium in Age-Related Macular Degeneration: A Prospective Trial. Investig Opthalmol Vis Sci. [Internet]. 2004 [cited 2019 Feb 21];45:4151. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15505069
- Ma Z, Han L, Wang C, et al. Autologous transplantation of retinal pigment epithelium-bruch’s membrane complex for hemorrhagic age-related macular degeneration. Investig Opthalmol Vis Sci. [Internet]. 2009 [cited 2019 Feb 21];50:2975. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19117919
- Parolini B, Grewal DS, Pinackatt SJ, et al. Combined autologous transplantation of neurosensory retina, retinal pigment epithelium, and choroid free grafts. Retina. [Internet]. 2018 [cited 2019 Feb 21];38(Suppl 1):S12–S22. Available from. : http://insights.ovid.com/crossref?an=00006982-201809001-00004
- Machemer R, Steinhorst UH. Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol. [Internet]. 1993 [cited 2019 Feb 21];231:635–641. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8258397
- Akduman L, Karavellas MP, MacDonald JC, et al. Macular translocation with retinotomy and retinal rotation for exudative age-related macular degeneration. Retina. [Internet]. 1999 [cited 2019 Feb 21];19:418–423. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10546938
- Abdel-Meguid A, Lappas A, Hartmann K, et al. One year follow up of macular translocation with 360 degree retinotomy in patients with age related macular degeneration. Br J Ophthalmol. [Internet]. 2003 [cited 2019 Feb 21];87:615–621. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12714406
- Todorich B, Scott IU, HW F, et al. Evolving Strategies in the Management of Submacular Hemorrhage Associated With Choroidal Neovascularization in the Anti–Vascular Endothelial Growth Factor Era. Retina. [Internet]. 2011 [cited 2019 Feb 17];31:1749–1752. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21562448
- Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol. Am J Ophthalmol. [Internet]. 2003 [cited 2019 Mar 2];135:194–205. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12566024
- Schulze-Bonsel K, Feltgen N, Burau H, et al. Visual Acuities “Hand Motion” and “Counting Fingers” Can Be Quantified with the Freiburg Visual Acuity Test. Investig Opthalmol Vis Sci. [Internet]. 2006 [cited 2019 Mar 2];47:1236. Available from:
- Holladay JT. Proper method for calculating average visual acuity. J Refract Surg. [Internet]. 1997 [cited 2019 Mar 8];13:388–391. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9268940
- Lange C, Feltgen N, Junker B, et al. Resolving the clinical acuity categories “hand motion” and “counting fingers” using the Freiburg Visual Acuity Test (FrACT). Graefes Arch Clin Exp Ophthalmol. [Internet]. 2009 [cited 2019 Mar 2];247:137–142. Available from: http://link.springer.com/10.1007/s00417-008-0926-0
- Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. [Internet]. 2010 [cited 2019 Mar 8];30:1046–1050. Available from: https://insights.ovid.com/crossref?an=00006982-201007000-00008
- Stroman WR, Gross JG, Taylor RJ, et al. Current treatment strategies for submacular hemorrhage. Expert Rev Ophthalmol. [Internet]. 2017;12:159–172. Available from
- Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. [Internet]. 2006 [cited 2019 Feb 22];355:1419–1431. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa054481
- Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration. N Engl J Med. [Internet]. 2006 [cited 2019 Feb 22];355:1432–1444. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa062655
- Group TCR. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. [Internet]. 2011 [cited 2019 Feb 22];364:1897–1908. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa1102673
- Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. [Internet]. 2012 [cited 2019 Feb 22];119:2537–2548. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23084240
- Stifter E, Michels S, Prager F, et al. Intravitreal Bevacizumab Therapy for Neovascular Age-related Macular Degeneration with Large Submacular Hemorrhage. Am J Ophthalmol. [Internet]. 2007 [cited 2019 Feb 22];144:886–892.e2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17916314
- Chang MA, Do DV, Bressler SB, et al. Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina. [Internet]. 2010 [cited 2019 Feb 22];30:1171–1176. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20827138
- Altaweel MM, Daniel E, Martin DF, et al. Outcomes of eyes with lesions composed of >50% blood in the comparison of age-related macular degeneration treatments trials (CATT). Ophthalmology. [Internet]. 2015 [cited 2019 Feb 22];122:391–398.e5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25307130
- Lazzeri S, Figus M, Sartini MS, et al. Intravitreal Ranibizumab for Predominantly Hemorrhagic Choroidal Neovascularization in Age-Related Macular Degeneration. Ophthalmologica. [Internet]. 2015 [cited 2019 Feb 23];233:74–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25662794
- Cho HJ, Koh KM, Kim HS, et al. Anti–vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol. [Internet]. 2013 [cited 2019 Feb 17];156:524–531.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23769197
- Kim KH, Kim JH, Chang YS, et al. Clinical outcomes of eyes with submacular hemorrhage secondary to age-related macular degeneration treated with anti-vascular endothelial growth factor. Korean J Ophthalmol. [Internet]. 2015 [cited 2019 Feb 22];29:315–324. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26457037
- Kim JH, Lee DW, Choi SC, et al. Intravitreal anti-vascular endothelial growth factor for newly diagnosed symptomatic polypoidal choroidal vasculopathy with extrafoveal polyps. Korean J Ophthalmol. [Internet]. 2015 [cited 2019 Mar 25];29:404–410. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26635457
- Chang YS, Kim JH, Kim JW, et al. Polypoidal choroidal vasculopathy in patients aged less than 50 years: characteristics and 6-month treatment outcome. Graefes Arch Clin Exp Ophthalmol. [Internet]. 2016 [cited 2019 Mar 25];254:1083–1089. Available from: http://link.springer.com/10.1007/s00417-015-3173-1
- Kim JH, Chang YS, Kim JW, et al. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization. Ophthalmology. [Internet]. 2014 [cited 2019 Feb 17];121:926–935. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24342019
- Kokame GT. Prospective evaluation of subretinal vessel location in polypoidal choroidal vasculopathy (PCV) and response of hemorrhagic and exudative PCV to high-dose antiangiogenic therapy (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. [Internet]. 2014 [cited 2019 Mar 26];112:74–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25646029
- Cho HJ, Koh KM, Kim JH, et al. Intravitreal ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration. Retina. [Internet]. 2015 [cited 2019 Feb 17];35:205–212. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25105310
- Dimopoulos S, Leitritz MA, Ziemssen F, et al. Submacular predominantly hemorrhagic choroidal neovascularization: resolution of bleedings under anti-VEGF therapy. Clin Ophthalmol. [Internet]. 2015 [cited 2019 Mar 25];9:1537–1541. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26346691
- Kim HS, Cho HJ, Yoo SG, et al. Intravitreal anti-vascular endothelial growth factor monotherapy for large submacular hemorrhage secondary to neovascular age-related macular degeneration. Eye (Lond). [Internet]. 2015 [cited 2019 Mar 8];29:1141–1151. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26272443
- Shin K-H, Lee TG, Kim JH, et al. The efficacy of intravitreal aflibercept in submacular hemorrhage secondary to wet age-related macular degeneration. Korean J Ophthalmol. [Internet]. 2016 [cited 2019 Feb 26];30:369. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27729757
- Karagiannis D, Chatziralli I, Kaprinis K, et al. Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration. Clin Interv Aging. [Internet]. 2017 [cited 2019 Mar 8];12:1829–1833. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29138543
- Kang HG, Kang H, Byeon SH, et al. Long-term visual outcomes for treatment of submacular haemorrhage secondary to polypoidal choroidal vasculopathy. Clin Experiment Ophthalmol. [Internet]. 2018 [cited 2019 Mar 25];46:916–925.
- McKibbin M, Papastefanou V, Matthews B, et al. Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration. Eye. [Internet]. 2010 [cited 2019 Mar 2];24:994–998. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19911016
- Jain S, Kishore K, Sharma YR. Intravitreal anti-VEGF monotherapy for thick submacular hemorrhage of less than 1 week duration secondary to neovascular age-related macular degeneration. Indian J Ophthalmol. [Internet]. 2013 [cited 2019 Mar 25];61:490–496. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24104707
- Shienbaum G, Garcia Filho CAA, Flynn HW, et al. Management of submacular hemorrhage secondary to neovascular age-related macular degeneration with anti–vascular endothelial growth factor monotherapy. Am J Ophthalmol. [Internet]. 2013 [cited 2019 Feb 26];155:1009–1013. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23465269
- Iacono P, Parodi MB, Introini U, et al. Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration. Retina. [Internet]. 2014 [cited 2019 Feb 26];34:281–287. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23851632
- Chang AA, Broadhead GK, Hong T, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration: 12-month safety and efficacy outcomes. Ophthalmic Res. [Internet]. 2015 [cited 2019 Feb 26];55:84–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26637166
- Sarao V, Parravano M, Veritti D, et al. Intravitreal aflibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapy. Retina. [Internet]. 2016 [cited 2019 Feb 26];36:770–777. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26398691
- Willoughby AS, Ying G, Toth CA, et al. Subretinal hyperreflective material in the comparison of age-related macular degeneration treatments trials. Ophthalmology. [Internet]. 2015 [cited 2019 Mar 28];122:1846–1853.e5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26143666
- Kim JH, Chang YS, Kim JW, et al. Morphologic features associated with fibrotic scarring after anti–vascular endothelial growth factor therapy in polypoidal choroidal vasculopathy. Retina. [Internet]. 2018 [cited 2019 Mar 25];38:2168–2176. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28930802
- Mizutani T, Yasukawa T, Ito Y, et al. Pneumatic displacement of submacular hemorrhage with or without tissue plasminogen activator. Graefe’s Arch Clin Exp Ophthalmol. [Internet]. 2011 [cited 2019 Mar 8];249:1153–1157. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21445629
- Fujikawa M, Sawada O, Miyake T, et al. Comparison of pneumatic displacement for submacular hemorrhages with gas alone and gas plus tissue plasminogen activator. Retina. [Internet]. 2013 [cited 2019 Mar 8];33:1908–1914. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23594720
- Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol. [Internet]. 1994 [cited 2019 Apr 18];118:559–568. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7977569
- Shin JY, Lee J, Byeon SH. Anti–vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage. Am J Ophthalmol. [Internet]. 2015 [cited 2019 Feb 17];159:904–914.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25637179
- Hillenkamp J, Surguch V, Framme C, et al. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefe’s Arch Clin Exp Ophthalmol. [Internet]. 2010 [cited 2019 Feb 26];248:5–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19669780
- de Jong JH, van Zeeburg EJT, Cereda MG, et al. Intravitreal versus subretinal administration of recombinant tissue plasminogen activator combined with gas for acute submacular hemorrhages due to age-related macular degeneration. Retina. [Internet]. 2016 [cited 2019 Feb 27];36:914–925. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26807631
- Guthoff R, Guthoff T, Meigen T, et al. Intravitreous injection of bevacizumab, tissue plasminogen activator, and gas in the treatment of submacular hemorrhage in age-related macular degeneration. Retina. [Internet]. 2011 [cited 2019 Mar 1];31:36–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20921929
- Kitagawa Y, Shimada H, Mori R, et al. Intravitreal tissue plasminogen activator, ranibizumab, and gas injection for submacular hemorrhage in polypoidal choroidal vasculopathy. Ophthalmology. [Internet]. 2016 [cited 2019 Feb 17];123:1278–1286. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26949121
- Lee JP, Park JS, Kwon OW, et al. Management of acute submacular hemorrhage with intravitreal injection of tenecteplase, anti-vascular endothelial growth factor and gas. Korean J Ophthalmol. [Internet]. 2016 [cited 2019 Feb 17];30:192–197. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27247518
- Martel JN, Mahmoud TH. Subretinal pneumatic displacement of subretinal hemorrhage. JAMA Ophthalmol. [Internet]. 2013 [cited 2019 Feb 17];131:1632. Available from: http://archopht.jamanetwork.com/article.aspx?doi=10.1001/jamaophthalmol.2013.5464
- Yiu G, Mahmoud TH Subretinal hemorrhage. Dev Ophthalmol. [Internet]. 2014 [cited 2019 Feb 17]. 213–222. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25196772.
- Kadonosono K, Arakawa A, Yamane S, et al. Displacement of submacular hemorrhages in age-related macular degeneration with subretinal tissue plasminogen activator and air. Ophthalmology. [Internet]. 2015 [cited 2019 Apr 18];122:123–128. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25200400
- Sharma S, Kumar JB, Kim JE, et al. Pneumatic displacement of submacular hemorrhage with subretinal air and tissue plasminogen activator. Ophthalmol Retin. [Internet]. 2018 [cited 2019 Apr 18];2:180–186. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2468653017302786
- Kimura S, Morizane Y, Matoba R, et al. Retinal sensitivity after displacement of submacular hemorrhage due to polypoidal choroidal vasculopathy: effectiveness and safety of subretinal tissue plasminogen activator. Jpn J Ophthalmol. [Internet]. 2017 [cited 2019 Feb 17];61:472–478. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28836011
- Novelli FJD, Preti RC, Monteiro MLR, et al. A new method of subretinal injection of tissue plasminogen activator and air in patients with submacular hemorrhage. Retina. [Internet]. 2017 [cited 2019 Feb 17];37:1607–1611. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28129217
- Treumer F, Wienand S, Purtskhvanidze K, et al. The role of pigment epithelial detachment in AMD with submacular hemorrhage treated with vitrectomy and subretinal co-application of rtPA and anti-VEGF. Graefe’s Arch Clin Exp Ophthalmol. [Internet]. 2017 [cited 2019 Mar 2];255:1115–1123. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28280989
- Juncal VR, Hanout M, Altomare F, et al. Surgical management of submacular hemorrhage: experience at an academic Canadian centre. Can J Ophthalmol. [Internet]. 2018 [cited 2019 Feb 17];53:408–414. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30119797
- Ozkaya A, Erdogan G, Tarakcioglu HN. Submacular hemorrhage secondary to age-related macular degeneration managed with vitrectomy, subretinal injection of tissue plasminogen activator, hemorrhage displacement with liquid perfluorocarbon, gas tamponade, and face-down positioning. Saudi J Ophthalmol Off J Saudi Ophthalmol Soc. [Internet]. 2018 [cited 2019 Feb 17];32:269–274. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30581295
- Kim LA, Eliott D. Management of submacular hemorrhage in age-related macular degeneration. Ophthalmol Retin. [Internet]. 2018 [cited 2019 Apr 18];2:177–179. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2468653017306905
- Treumer F, Klatt C, Roider J, et al. Subretinal coapplication of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular haemorrhage. Br J Ophthalmol. [Internet]. 2010 [cited 2019 Mar 1];94:48–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19946027
- Sandhu SS, Manvikar S, Steel DHW. Displacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumab. Clin Ophthalmol. [Internet]. 2010 [cited 2019 Mar 1];4:637–642. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20668667
- Treumer F, Roider J, Hillenkamp J. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage. Br J Ophthalmol. [Internet]. 2012 [cited 2019 Feb 17];96:708–713. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22174095
- Chang W, Garg SJ, Maturi R, et al. Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration. Am J Ophthalmol. [Internet]. 2014 [cited 2019 Feb 17];157:1250–1257. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24531021
- Kimura S, Morizane Y, Hosokawa M, et al. Submacular hemorrhage in polypoidal choroidal vasculopathy treated by vitrectomy and subretinal tissue plasminogen activator. Am J Ophthalmol. [Internet]. 2015 [cited 2019 Feb 17];159:683–689.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25555798
- González-López JJ, McGowan G, Chapman E, et al. Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive cases. Eye. [Internet]. 2016 [cited 2019 Mar 1];30:929–935. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27055681
- Kumar A, Roy S, Bansal M, et al. Modified approach in management of submacular hemorrhage secondary to wet age-related macular degeneration. Asia-Pacific J Ophthalmol (Philadelphia, Pa). [Internet]. 2016 [cited 2019 Feb 26];5:143–146. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26302314
- Haupert CL, McCuen BW, Jaffe GJ, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol. [Internet]. 2001 [cited 2019 Feb 17];131:208–215. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11228297
- Wood EH, Rao P, Mahmoud TH. NanoVitreoRetinal (NVR) subretinal gateway device to displace submacular hemorrhage: access to the subretinal space without vitrectomy. Retina. 2019 Forthcoming.
- Feng H, Aadelman RA. Cataract formation following vitreoretinal procedures. Clin Ophthalmol. 2014;8:1957–1965.
- Patel JI, Hykin PG, Cree IA. Diabetic cataract removal: postoperative progression of maculopathy-growth factor and clinical analysis. Br J Ophthalmol. 2006;90:697–701.
- Roller AB, Mahajan VB, Boldt HC, et al. Effects of vitrectomy on age-related macular degeneration. Ophthalmology. 2010;117:1381–1386.
- Shin Y-I, Sung J-Y, Sagong M, et al. Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage. Sci Rep. [Internet]. 2018 [cited 2019 Feb 17];8:10560. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30002432
- Kimura M, Yasukawa T, Shibata Y, et al. Flattening of retinal pigment epithelial detachments after pneumatic displacement of submacular hemorrhages secondary to age-related macular degeneration. Graefe’s Arch Clin Exp Ophthalmol. 2018;256:1823–1829.
- Stanescu-Segall D, Balta F, Jackson TL. Submacular hemorrhage in neovascular age-related macular degeneration: A synthesis of the literature. Surv Ophthalmol. [Internet]. 2016 [cited 2019 Feb 17];61:18–32. Available from : http://www.ncbi.nlm.nih.gov/pubmed/26212151
- Campochiaro PA, Marcus DM, Awh CC, et al. The port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. [Internet]. 2019 [cited 2019 Oct 1];126:1141–1154. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30946888